Skip to main navigation Skip to search Skip to main content

A Trapping-Micro-LC-FAIMS/dCV-MS Strategy for Ultrasensitive and Robust Targeted Quantification of Protein Drugs and Biomarkers

  • Qingqing Shen
  • , Jie Pu
  • , Chao Xue
  • , Ming Zhang
  • , Yang Qu
  • , Shihan Huo
  • , Michael Belford
  • , Charles Maxey
  • , Neloni Wijeratne
  • , Claudia Martins
  • , Scott Peterman
  • , Wei Jun Qian
  • , Cornelia Boeser
  • , Jun Qu
  • SUNY Buffalo
  • Bristol-Myers Squibb
  • Thermo Fisher Scientific, Inc.
  • Pacific Northwest National Laboratory

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The sensitivity of LC-MS in quantifying target proteins in plasma/tissues is significantly hindered by coeluted matrix interferences. While antibody-based immuno-enrichment effectively reduces interferences, developing and optimizing antibodies are often time-consuming and costly. Here, by leveraging the orthogonal separation capability of Field Asymmetric Ion Mobility Spectrometry (FAIMS), we developed a FAIMS/differential-compensation-voltage (FAIMS/dCV) method for antibody-free, robust, and ultrasensitive quantification of target proteins directly from plasma/tissue digests. By comparing the intensity-CV profiles of the target vs coeluted endogenous interferences, the FAIMS/dCV approach identifies the optimal CV for quantification of each target protein, thus maximizing the signal-to-noise ratio (S/N). Compared to quantification without FAIMS, this technique dramatically reduces endogenous interferences, showing a median improvement of the S/N by 14.8-fold for the quantification of 17 representative protein drugs and biomarkers in plasma or tissues and a 5.2-fold median increase in S/N over conventional FAIMS approach, which uses the peak CV of each target. We also discovered that the established CV parameters remain consistent over months and are matrix-independent, affirming the robustness of the developed FAIMS/dCV method and the transferability of the method across matrices. The developed method was successfully demonstrated in three applications: the quantification of monoclonal antibodies with subng/mL LOQ in plasma, an investigation of the time courses of evolocumab and its target PCSK9 in a preclinical setting, and a clinical investigation of low abundance obesity-related biomarkers. This innovative and easy-to-use method has extensive potential in clinical and pharmaceutical research, particularly where sensitive and high-throughput quantification of protein drugs and biomarkers is required.

Original languageEnglish
Pages (from-to)13140-13149
Number of pages10
JournalAnalytical Chemistry
Volume96
Issue number32
DOIs
StatePublished - Aug 13 2024

Fingerprint

Dive into the research topics of 'A Trapping-Micro-LC-FAIMS/dCV-MS Strategy for Ultrasensitive and Robust Targeted Quantification of Protein Drugs and Biomarkers'. Together they form a unique fingerprint.

Cite this